dong li

Dr. dong li


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2020 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
DLdong li
dong li
TWTao Wang
Tao Wang
FSFei-Fan Sun
Fei-Fan Sun
JFJian-Qiong Feng
Jian-Qiong Feng
JPJing-Jing Peng
Jing-Jing Peng
TZTao Zhang
Tao Zhang

15 July 2024 in Medcomm
Verified
Journal Article
Open access
CXChuan Xu
Chuan Xu
CJChaoyang Jiang
Chaoyang Jiang
ZLZhihui Li
Zhihui Li
HGHui Gao
Hui Gao
JXJing Xian
Jing Xian
DLdong li
dong li
Exosomes are nanoscale vesicles of cellular origin. One of the main characteristics of exosomes is their ability to carry a wide range of biomolecules from their parental cells, which are important mediators of intercellular communication and play an important role in physiological and pathological processes. Exosomes have the advantages of biocompatibility, low immunogenicity, and wide biodistribution. As researchers’ understanding of exosomes has increased, various strategies have been proposed for their use in diagnosing and treating diseases. Here, we provide an overview of the biogenesis and composition of exosomes, describe the relationship between exosomes and disease progression, and focus on the use of exosomes as biomarkers for early screening, disease monitoring, and guiding therapy in refractory diseases such as tumors and neurodegenerative diseases. We also summarize the current applications of exosomes, especially engineered exosomes, for efficient drug delivery, targeted therapies, gene therapies, and immune vaccines. Finally, the current challenges and potential research directions for the clinical application of exosomes are also discussed. In conclusion, exosomes, as an emerging molecule that can be used in the diagnosis and treatment of diseases, combined with multidisciplinary innovative solutions, will play an important role in clinical applications.

10 December 2020 in Oncology Research
Verified
Journal Article
Open access
DLdong li
dong li
FSFei-Fan Sun
Fei-Fan Sun
DWDan Wang
Dan Wang
TWTao Wang
Tao Wang
JPJing-Jing Peng
Jing-Jing Peng
TZTao Zhang
Tao Zhang
Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug resistance and suppressed the migration, invasion, colony formation, and tumorigenesis in sorafenib-resistant hepatoma cells in vitro and in vivo. Mechanistic investigations indicated that loss of microRNA-1 (miR-1), a tumor-suppressive microRNA, contributed to the PD-L1 upregulation in sorafenib-resistant hepatoma cells, and PD-L1 was a direct regulatory target of miR-1. Further study revealed that an oncogenic transcriptional factor, nuclear factor E2-related factor 2 (NRF-2), was induced in sorafenib-resistant hepatoma cells and inhibited expression of miR-1 in vitro. From molecular mechanism insight back to the functional verification, we eventually demonstrated that miR-1 executed its tumor-suppressive effects on drug resistance and other malignant properties in sorafenib-resistant hepatoma cells partially by PD-L1 inhibition in vitro and in vivo. In conclusion, our data suggested that a NRF-2/miR-1/PD-L1 regulatory axis contributed to the development and maintenance of drug resistance and other tumorigenic properties in sorafenib-resistant hepatoma cells and provided a potential therapeutic target for overcoming sorafenib resistance in HCC.

27 November 2014 in FEBS Letters
Verified
Journal Article
Closed access
DLdong li
dong li
YLYu Liu
Yu Liu
HLHua Li
Hua Li
JPJing-Jing Peng
Jing-Jing Peng
YTYan Tan
Yan Tan
TZTao Zhang
Tao Zhang

16 October 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
DHDan He
Dan He
ZLZhiHui Li
ZhiHui Li
MWMin Wang
Min Wang
DKDejun Kong
Dejun Kong
WGWenyan Guo
Wenyan Guo
DZDaijun zhou
Daijun zhou
In patients with abdominal or pelvic tumors, radiotherapy can result in radiation-induced intestinal injury (RIII), a potentially severe complication for which there are few effective therapeutic options. Sitagliptin (SI) is an oral hypoglycemic drug that exhibits antiapoptotic, antioxidant, and anti-inflammatory activity, but how it influences RIII-associated outcomes has yet to be established. In this study, a pH-responsive metal-organic framework-based nanoparticle platform was developed for the delivery of SI (SI@ZIF-8@MS NP). These NPs incorporated mPEG-b-PLLA (MS) as an agent capable of resisting the effects of gastric acid, and are capable of releasing Zn2+ ions. MS was able to effectively shield these SI@ZIF-8 NPs from rapid degradation when exposed to an acidic environment, enabling the subsequent release of SI and Zn2+ within the intestinal fluid. Notably, SI@ZIF-8@MS treatment was able to mitigate radiation-induced intestinal dysbiosis in these mice. restored radiation-induced changes in bacterial composition. In summary, these data demonstrate the ability of SI@ZIF-8@MS to protect against WAI-induced intestinal damage in mice, suggesting that these NPs represent a multimodal targeted therapy that can effectively be used in the prevention or treatment of RIII.

4 July 2024 in Microbial Pathogenesis
Verified
Journal Article
Closed access
JDJieyin Deng
Jieyin Deng
YHYe Huang
Ye Huang
KYKe Yu
Ke Yu
HLHong Luo
Hong Luo
DZDaijun zhou
Daijun zhou
DLdong li
dong li